Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease
- PMID: 30392802
- DOI: 10.1016/j.jvir.2018.08.007
Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease
Abstract
Three patients with a medical history of breast carcinoma and metastatic carcinomatous liver disease associated with severe portal hypertension and refractory ascites are presented. Transjugular intrahepatic portosystemic shunt creation was considered as a palliative treatment option and a valuable alternative to regular paracenteses in these patients. In 2 of the 3 patients, the refractory ascites was controlled for several months without need for paracentesis, and subsequently transjugular intrahepatic portosystemic shunt may provide valuable palliation and ascites control in patients with refractory ascites due to breast cancer-induced pseudocirrhosis.
Copyright © 2018 SIR. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The Role of TIPS in patients with Refractory Ascites and Portal Vein Thrombosis.Ann Hepatol. 2017 Jul-Aug;16(4):619-620. doi: 10.5604/01.3001.0010.0310. Ann Hepatol. 2017. PMID: 28611269
-
Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.Eur J Gastroenterol Hepatol. 2019 May;31(5):626-632. doi: 10.1097/MEG.0000000000001342. Eur J Gastroenterol Hepatol. 2019. PMID: 30550458
-
Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.Eur J Gastroenterol Hepatol. 2006 Nov;18(11):1143-50. doi: 10.1097/01.meg.0000236872.85903.3f. Eur J Gastroenterol Hepatol. 2006. PMID: 17033432 Review.
-
Urinary aquaporin-2 excretion before and after transjugular intrahepatic portosystemic shunt insertion for refractory ascites.Scand J Gastroenterol. 2015 Apr;50(4):454-61. doi: 10.3109/00365521.2014.962610. Epub 2015 Jan 30. Scand J Gastroenterol. 2015. PMID: 25637473
-
The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S344-51. doi: 10.1097/MCG.0b013e318157e500. J Clin Gastroenterol. 2007. PMID: 17975487 Review.
Cited by
-
Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature.Dig Dis Sci. 2024 Mar;69(3):1004-1014. doi: 10.1007/s10620-023-08226-3. Epub 2024 Jan 4. Dig Dis Sci. 2024. PMID: 38175453 Free PMC article. Review.
-
Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity.ESMO Open. 2020 Jun;5(3):e000695. doi: 10.1136/esmoopen-2020-000695. ESMO Open. 2020. PMID: 32487541 Free PMC article.
-
Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis.Sci Rep. 2022 Nov 18;12(1):19865. doi: 10.1038/s41598-022-24241-2. Sci Rep. 2022. PMID: 36400809 Free PMC article.
-
Risks and benefits of TIPS in HCC and other liver malignancies: a literature review.BMC Gastroenterol. 2023 Nov 20;23(1):403. doi: 10.1186/s12876-023-03047-0. BMC Gastroenterol. 2023. PMID: 37986043 Free PMC article. Review.
-
Transjugular intrahepatic portosystemic shunt for the management of symptomatic malignant pseudocirrhosis.J Gastrointest Oncol. 2022 Feb;13(1):279-287. doi: 10.21037/jgo-21-501. J Gastrointest Oncol. 2022. PMID: 35284108 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical